JPMorgan has reinstated ratings and price targets on 14 major biotechnology firms, arguing that the large-cap biotech sector is approaching a pivotal moment where clinical pipeline wins are translating into steady commercial revenue streams.
In a report led by analyst Jessica Fye, the bank notes that a subset of companies has moved into sustained profitability while others are approaching that threshold. The combination of improving margins, broader commercial footprints and a sequence of clinical catalysts are cited as factors positioning the sector for long-term expansion.
The report singled out several names that have already become profitable, including Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC) and Ascendis Pharma AS (NASDAQ:ASND). Insmed Inc (NASDAQ:INSM) and Ionis are described as being close to achieving profitability.
JPMorgan also emphasized diversification initiatives across the group. Examples noted in the report include Vertex Pharmaceuticals Inc expanding into renal disease, BioMarin reinforcing its rare disease portfolio through acquisitions, and Moderna applying its mRNA platform to oncology programs. The bank views these moves as part of a broader strategy among large-cap biotechs to build multi-product commercial franchises and reduce dependence on single-product models.
Analysts highlighted a steady schedule of upcoming clinical updates that could serve as catalysts for share price movement and sector sentiment. Specific trials referenced include high-profile cardiovascular outcomes studies tied to Ionis’s partnered drugs and pivotal renal readouts expected from Vertex, both of which JPMorgan views as potential inflection points for the companies involved.
On recommendations, JPMorgan assigned "Overweight" ratings to Vertex (NASDAQ:VRTX), Alnylam, BeOne, United Therapeutics Corporation (NASDAQ:UTHR), Insmed, Ascendis, Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis, BioMarin and Mirum. The bank placed BioNTech, Incyte and Halozyme at "Neutral," while assigning an "Underweight" rating to Moderna, citing financial risks despite its oncology progress.
JPMorgan also provided price targets set for December 2026. Those include $515 for Vertex, $420 for Alnylam, $415 for BeOne, $685 for United Therapeutics and $180 for Insmed. Moderna was assigned a $40 target and BioNTech a $100 target.
The report framed the sector outlook around three converging trends: profit momentum as more companies reach sustained positive earnings, business diversification that broadens addressable markets, and an active clinical calendar that could produce material readouts. "Several biotechs are converting pipeline success into profitable franchises," the analysts wrote, underlining confidence that firms can scale beyond reliance on single products.
With profitability gains, diversification strategies and clinical catalysts aligning, JPMorgan concluded that the large-cap biotech sector is entering a new phase of durable expansion, reinstating coverage to reflect that view across 14 names.
Key points
- JPMorgan reinstated ratings and price targets on 14 large-cap biotech companies and described the sector as being at an inflection point.
- Several firms have achieved sustained profitability while others are close, and diversification efforts are expanding commercial franchises.
- Upcoming clinical readouts, including cardiovascular outcomes trials and pivotal renal results, were identified as potential catalysts for the group.
Risks and uncertainties
- Moderna faces financial risks despite progress in oncology, according to JPMorgan - this affects investor outlook for that company and could influence sector sentiment.
- The timing and results of key clinical readouts could materially affect individual companies and broader sector momentum; those readouts are upcoming and cited as potential catalysts.
- Many companies remain in the process of scaling commercial operations beyond single-product reliance, which carries execution risk as firms seek sustained margin expansion.